NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis $1.05 -0.06 (-5.41%) Closing price 11/19/2026 04:00 PM EasternExtended Trading$1.11 +0.06 (+5.62%) As of 11/19/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Gain Therapeutics Stock (NASDAQ:GANX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gain Therapeutics alerts:Sign Up Key Stats Today's Range$1.03▼$1.1450-Day Range$0.94▼$1.9552-Week Range$0.94▼$4.34Volume552,856 shsAverage Volume761,411 shsMarket Capitalization$46.76 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingModerate Buy Company Overview Gain Therapeutics, Inc. is a biotechnology company developing small-molecule treatments for neurological and other diseases linked to dysfunctional proteins. Its research focuses on conditions for which existing therapies may not address the underlying protein dysfunction. The company uses its discovery platform, which combines computational methods and structural biology, to identify previously unexplored binding sites on proteins. It aims to develop compounds that bind at these sites and help restore protein function. Gain Therapeutics’ lead program, GT-02287, is an oral investigational therapy being developed for Parkinson’s disease, including disease associated with GBA1 mutations. The company is also pursuing drug-discovery programs for other neurological and lysosomal disorders.AI Generated. May Contain Errors. Read More Gain Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreGANX MarketRank™: 2.28814723252 of 5 starsGain Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 533rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingGain Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialGain Therapeutics has a consensus price target of $7.67, representing about 630.2% upside from its current price of $1.05.Amount of Analyst CoverageGain Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Gain Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gain Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.30% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 5.55.Change versus previous monthShort interest in Gain Therapeutics has recently increased by 21.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.01 News SentimentGain Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Gain Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for GANX on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.15% of the stock of Gain Therapeutics is held by insiders.Percentage Held by Institutions11.97% of the stock of Gain Therapeutics is held by institutions.Read more about Gain Therapeutics' insider trading history. Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GANX Stock News HeadlinesGain Therapeutics Reports Stable Motor Scores and Biomarker Findings for Rexaceract in Phase 1b Parkinson’s Study; Presents Encouraging Preclinical Data for GT-04686November 17 at 4:30 PM | quiverquant.comQGain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686November 17 at 4:15 PM | globenewswire.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it. | Paradigm Press (Ad)HC Wainwright Lifts Earnings Estimates for Gain TherapeuticsNovember 16, 2026 | americanbankingnews.comGain Therapeutics Q3 Loss NarrowsNovember 10, 2026 | rttnews.comGain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateNovember 10, 2026 | globenewswire.comGain Therapeutics (GANX) Projected to Announce Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comGain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific ConferencesNovember 5, 2026 | globenewswire.comSee More Headlines GANX Stock Analysis - Frequently Asked Questions How have GANX shares performed this year? Gain Therapeutics' stock was trading at $3.22 at the start of the year. Since then, GANX shares have decreased by 67.4% and is now trading at $1.05. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) released its earnings results on Tuesday, November, 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,636,364 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Gain Therapeutics' major shareholders? Gain Therapeutics' top institutional shareholders include Marshall Wace LLP (3.77%), Hohimer Wealth Management LLC (0.76%), State Street Corp (0.46%) and Empowered Funds LLC (0.12%). Insiders that own company stock include Eric I Richman, Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder. View institutional ownership trends. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gain Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), IonQ (IONQ), Pfizer (PFE), Immunic (IMUX), Iovance Biotherapeutics (IOVA) and Aclaris Therapeutics (ACRS). Company Calendar Last Earnings11/10/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GANX's financial health is in the Red zone, according to TradeSmith. GANX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GANX CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees21Year Founded2017Price Target and Rating Average Price Target for Gain Therapeutics$7.67 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+630.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-133.17% Return on Assets-102.45% Debt Debt-to-Equity Ratio0.02 Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$50 thousand Price / Sales935.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book4.57Miscellaneous Outstanding Shares44,530,000Free Float42,677,000Market Cap$46.76 million OptionableOptionable Beta0.29 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:GANX) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.